
    
      The purpose of this study is to find out the effects of giving dabrafenib in combination with
      trametinib continuously with stereotactic radiotherapy (SRS) has on melanoma and brain
      metastases.

      Stereotactic Radiosurgery (SRS) is a non-surgical radiation therapy used to treat tumours of
      the brain. It can deliver precisely targeted radiation. Currently SRS alone is the usual
      treatment for patients with up to 4 brain lesions. This study will include 2 groups 1)
      patients with 1-4 brain lesions treated with SRS concurrently with dabrafenib and trametinib
      and 2) patients with 5-10 brain lesions treated with SRS concurrently with dabrafenib and
      trametinib.
    
  